SPOTLIGHT -
October 23rd 2023
Celltrion’s Zymfentra is subcutaneous version of infliximab.
July 10th 2023
Amgen’s Amjevita was already on the pharmacy benefit manager’s National Preferred Flex Formulary.
July 4th 2023
7 of them launched during the first several days of July, joining Amgen's Amjevita in the suddenly crowded market of Humira competitors. Pfizer’s Abrilada is the only FDA-approved Humira biosimilar that hasn’t launched.
July 1st 2023
Boehringer Ingelheim is pricing its biosimilar 5% to 7% below AbbVie’s top selling drug.
March 21st 2023
Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!